SO
RXRX icon

STRS Ohio’s Recursion Pharmaceuticals RXRX Stock Holding History

STRS Ohio’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-7,900
Closed -$52.1K – 2027
2024
Q3 		$52.1K Sell
7,900
-8,200
-51% -$58.8K ﹤0.01% 1797
2024
Q2 		$121K Sell
16,100
-4,200
-21% -$36.6K ﹤0.01% 1670
2024
Q1 		$202K Sell
20,300
-25,700
-56% -$286K ﹤0.01% 1551
2023
Q4 		$453K Hold
46,000
– – ﹤0.01% 1322
2023
Q3 		$351K Buy
46,000
+23,600
+105% +$235K ﹤0.01% 1403
2023
Q2 		$167K Buy
22,400
+1,700
+8% +$11.9K ﹤0.01% 1631
2023
Q1 		$138K Hold
20,700
– – ﹤0.01% 1671
2022
Q4 		$159K Hold
20,700
– – ﹤0.01% 1638
2022
Q3 		$220K Hold
20,700
– – ﹤0.01% 1582
2022
Q2 		$168K Buy
20,700
+6,100
+42% +$40.8K ﹤0.01% 1653
2022
Q1 		$104K Sell
14,600
-8,000
-35% -$85K ﹤0.01% 1834
2021
Q4 		$387K Buy
22,600
+16,000
+242% +$301K ﹤0.01% 1554
2021
Q3 		$151K Buy
6,600
+1,700
+35% +$48.2K ﹤0.01% 1858
2021
Q2 		$178K Buy
+4,900
New +$145K ﹤0.01% 1848

Other funds holding RXRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
MIC
Mubadala Investment Company Abu Dhabi, United Arab Emirates $20.5B AUM 19.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KA
Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

STRS Ohio's RXRX Position: Q4 2024 in Review

STRS Ohio sold out of Recursion Pharmaceuticals (RXRX) in Q4 2024, closing a stake of 7,900 shares — an estimated $52.1K sold.

STRS Ohio first reported a position in RXRX in Q2 2021 and held it in 14 quarters. The position peaked at $453K in Q4 2023. 316 funds tracked by Wall St. Rank hold RXRX as of Q4 2024.

  • STRS Ohio reported no remaining Recursion Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • STRS Ohio sold 7,900 Recursion Pharmaceuticals shares in Q4 2024, an estimated $52.1K.
  • STRS Ohio first reported a position in Recursion Pharmaceuticals in Q2 2021 and held it in 14 quarters.
  • STRS Ohio's Recursion Pharmaceuticals position peaked at $453K in Q4 2023.
  • 316 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q4 2024.

Based on STRS Ohio's 13F filing for Q4 2024, filed 28 May 2025.